CLARO MARK MABAZZA: Open Payments
NPI 1326617358 · BELLFLOWER, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,211 in 45 payments from 8 companies in 2025. Trend: 2023 $379 · 2024 $498 · 2025 $1,211
Food & beverage: $1,211
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $366 |
| Neurocrine BioSciences, Inc. | 8 | $255 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $159 |
| Janssen Pharmaceuticals, Inc | 1 | $141 |
| Otsuka America Pharmaceutical, Inc. | 1 | $104 |
| Bausch Health US, LLC | 5 | $103 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Alkermes, Inc. | 2 | $42 |
Products named: VRAYLAR, INGREZZA, CAPLYTA, INVEGA SUSTENNA, REXULTI, APLENZIN, FANAPT, ARISTADA.
Industry payments across CA — which companies pay providers there.
